An agonist antibody prefers relapsed AML for induction of cells that kill each other

• Published in: Scientific reports Vol. 9; no. 1; p. 3494
• Main Authors: Yea, Kyungmoo, Jones, Teresa M., Jung, Dokyung, Shin, Sanghee, Arlian, Britni M., Han, Kyung Ho, Zha, Zhao, Kim, Minseok S., Oh, Yong-Seok, Zhang, Hongkai, Lerner, Richard A.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 05.03.2019; Nature Publishing Group
• Subjects: 13/100; 64/60; 692/4017; 692/4028/67/1059; 82/1; Antibodies; Cancer; Cancer therapies; Chemotherapy; Cytotoxicity; Genotype & phenotype; Granzyme B; Humanities and Social Sciences; Killer cells; Leukemia; Lymphocytes B; Medical prognosis; Morphology; multidisciplinary; Perforin; Population; Science; Science (multidisciplinary); Stem cells; Thrombopoietin; Tumor cells; Tumors; Xenografts
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-40087-7

Previously, we reported an agonist antibody to a cytokine receptor, Thrombopoietin receptor (TPOR) that effectively induces cytotoxic killer cells from precursor tumor cells isolated from newly diagnosed AML patients. Here, we show that the TPOR agonist antibody can induce even relapsed AML cells into killer cells more potently than newly diagnosed AML cells. After stimulation by the agonist antibody, these relapsed leukemic cells enter into a differentiation process of killer cells. The antibody-induced killer cells express, Granzyme B and Perforin that assault and kill other members of the AML cell population. Particularly, the agonist antibody showed potent efficacy on the AML xenograft model in mice using the NOD/LtSz-scid IL2Rγc null (NSG) mice. These results show that the TPOR agonist antibody that induces AML cells to kill each other is effective on both relapsed AML cells and in vivo . Therefore, this study suggests a new strategy for the treatment of cancer relapse after chemotherapy.